Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Kush M Parmar, MD, PhD is a Managing Partner at 5AM Ventures. Dr. Parmar serves as a Chair or Director on the Boards of Ensoma, Entrada (NASDAQ: TRDA), GlycoEra, and Precede Bioscience. He previously served as Board Member or Observer for Akouos (acquired by Eli Lilly), Arvinas (NASDAQ: ARVN), Audentes (acquired by Astellas), Envoy (acquired by Takeda), Homology (NASDAQ: FIXX), Rallybio (NASDAQ: RLYB), scPharmaceuticals (NASDAQ: SCPH) and Vor Biopharma (NASDAQ: VOR) and as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J). Dr. Parmar serves on the Boards of Fellows of Harvard Medical School and Princeton University’s Department of Molecular Biology.
